Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Better Buy: Acadia Pharmaceuticals vs. Biogen
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
7 Things AbbVie's Top Executives Just Said That You'll Want to Know
7 Things AbbVie's Top Executives Just Said That You'll Want to Know
It's a good time to be AbbVie (NYSE: ABBV). And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong....
Humana (HUM) Q3 2017 Earnings Conference Call Transcript
Humana (HUM) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Humana (NYSE: HUM) Q3 2017 Earnings Conference CallNov. 8, 2017 9:00 pam. ETOperatorContinue readingSource: Fool.com
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
How to Invest in Biotech Stocks
How to Invest in Biotech Stocks
$33,800.That's how much you'd have if you'd invested $10,000 in Alnylam stock just one year ago.Sound enticing? How about $154,980?Continue readingSource: Fool.com
Here's Why Merck & Co., Inc. Tanked 14% in October
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Shares of U.K.-based Big Pharma giant GlaxoSmithKline (NYSE: GSK) tumbled during the month of October, according to data from S&P Global Market Intelligence, losing nearly $10 billion in....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
Novo Nordisk A/S Slogs Through the Year
Novo Nordisk A/S Slogs Through the Year
Novo Nordisk (NYSE: NVO) continues to slog through the year, dealing with losing exclusivity on hormone-replacement therapy Vagifem and pricing pressure. The year-over-year comparison for Vagifem....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Allergan Keeps Heading Lower. Is It Time to Buy?
Allergan Keeps Heading Lower. Is It Time to Buy?
Allergan's (NYSE: AGN) stock slid by double digits for the third straight month in October. So after dropping by another 13.5% last month, Allergan's stock has now lost around 30% of its value....
3 International Stocks for Retirees
3 International Stocks for Retirees
Retirees these days are living longer than ever before. That means there's a need to not only sustain your income with dividends, but also to grow your nest egg by investing in high-quality....
The Insurer That's Crushing It in Obamacare
The Insurer That's Crushing It in Obamacare
Worry that Obamacare is on life support doesn't seem to scare Centene Corporation (NYSE: CNC) CEO Michael Neidorff. Over the past few years, he's been significantly increasing Centene's exposure....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
The Only 3 Big Pharma Companies Growing Market Share
The Only 3 Big Pharma Companies Growing Market Share
With worldwide spending on prescription drugs increasing from an estimated $774 billion in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company....
Why Henry Schein, Inc. Is Falling
Why Henry Schein, Inc. Is Falling
In response to the company's third-quarter earnings, shares of Henry Schein (NASDAQ: HSIC), a maker of medical products that are primarily used by dentists and veterinarians, fell as much as 10%....
5 Dividend Aristocrats With the Fastest-Growing Dividends
5 Dividend Aristocrats With the Fastest-Growing Dividends
Many investors like to buy stocks that are known as Dividend Aristocrats. To join this elite group, an S&P 500 company must increase its dividend for at least 25 consecutive years. But just....
Affordable Care Act Enrollment: 5 Money-Saving Tips for 2018
Affordable Care Act Enrollment: 5 Money-Saving Tips for 2018
It's that time of the year again: Open enrollment for the Affordable Care Act (ACA), which you probably know better as Obamacare, is in full swing. Enrollment began on Nov. 1, as it has in recent....
These 3 Stocks Just Raised Their Dividends
These 3 Stocks Just Raised Their Dividends
Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall....
Why Celgene Crashed 30% in October -- and What Now?
Why Celgene Crashed 30% in October -- and What Now?
Few industry watchers expected much out of GED-0301, yet its failure in a phase 3 study, plus anemic sales growth for one of its most important drugs, caused Celgene Corp. (NASDAQ: CELG) shares to....
Why Exact Sciences Shares Rallied 16.7% in October
Why Exact Sciences Shares Rallied 16.7% in October
After reporting third-quarter financial results that were better than expected, Exact Sciences (NASDAQ: EXAS) shares gained 16.7% in October, according to S&P Global Market Intelligence.Exact....
Here's Why ViewRay, Inc. Is Rising Today
Here's Why ViewRay, Inc. Is Rising Today
After the company announced that it has received orders for a pair of MRIdian Linac systems, shares of ViewRay (NASDAQ: VRAY), a small-cap company focused on radiation therapy, jumped 17% as of....